Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Feb 4 2020

Full Issue

Promising HIV Vaccine Comes Up Short As Study Finds It Was No More Effective Than Placebo

“It’s disappointing, but I’m not overly surprised by it,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, which funded the $121 million research effort with the Bill & Melinda Gates Foundation. “It did not, essentially, bring it over the goal line.”

The Washington Post: Trial Of Promising HIV Vaccine Fails In South Africa

A broad study of a promising vaccine for HIV has ended in failure after an interim analysis showed it was no more effective than a placebo, researchers announced Monday. Vaccinations were halted after an independent monitoring panel for the “Uhambo” study in South Africa determined on Jan. 23 that 129 people who received the vaccine developed HIV while 123 who were given a placebo contracted the infection. (Bernstein, 2/3)

CNN: HIV Vaccine Trial Ends In 'Deep Disappointment'

"An HIV vaccine is essential to end the global pandemic, and we hoped this vaccine candidate would work. Regrettably, it does not," Dr. Anthony Fauci, director of the NIAID, said in a written statement on Monday. "Research continues on other approaches to a safe and effective HIV vaccine, which I still believe can be achieved," he said. (Howard, 2/3)

The Hill: Promising HIV Vaccine Trial In South Africa Fails

Late last month, an interim analysis found 129 HIV infections occurred among the vaccine recipients and 123 HIV infections occurred among the placebo recipients. There were no safety concerns, but the NIH said it agreed with an independent safety board that since the vaccines did not work, the study should stop. (Weixel, 2/3)

In other pharmaceutical news —

The Wall Street Journal: Patients Often Get Antibiotics Without A Doctor Visit, Study Finds

Patients widely received antibiotics with no record of seeing a doctor, a nationwide study found, despite recommendations that doctors physically screen patients to prevent unnecessary prescriptions that could contribute to superbugs. Researchers from Brigham and Women’s Hospital and Northwestern University looked through a decade of medical bills for 53 million people nationwide. They found nearly 83 million antibiotic prescriptions that were filled with no record of an associated doctor visit that could have verified that the antibiotics were necessary. (Evans, 2/3)

Stat: Andreessen Horowitz Launching Its Third Life Sciences Fund

Marc Andreessen, famous for proclaiming that software was “eating the world,” said in 2009 that the one place his eponymous Silicon Valley venture capital firm would never invest was health care. How things have changed. On Tuesday, Andreessen Horowitz launched its third fund dedicated exclusively to health and biology. Biofund III, as the $750 million investment vessel is called, will be directed at startups looking to do everything from design better drugs to improve the way people deliver and receive health care. (Brodwin, 2/4)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, June 2
  • Monday, June 1
  • Friday, May 29
  • Thursday, May 28
  • Wednesday, May 27
  • Tuesday, May 26
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF